Drug Profile
Research programme: fms-like tyrosine kinase 3/cyclin dependent kinase 4 inhibitors - Amgen
Alternative Names: AM-5992; flt3/CDK4 dual kinase inhibitor - AmgenLatest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Amgen
- Class Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 27 Mar 2023 Discontinued - Preclinical for Acute myeloid leukaemia in USA (PO)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (PO)
- 20 Oct 2013 Pharmacodynamics data for AMG 5992 from a preclinical trial in Acute myeloid leukaemia presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2013)